ORGANIC NETWORK SYNTHESIS

A Critical Evaluation of the Seth S. Margolis Models of Alzheimer's Disease Pathogenesis

Margolis

Critical Review — Editor Protocol Applied

AdultCognitiveDisease.com
March 2026

Prepared for Dr. James Truchard and Benjamin Gustafsson
Drafted by Claude-Opus-4.6

Synaptic Restriction and Proteostatic Collapse: Evaluation of Margolis Models in Alzheimer's Disease Pathogenesis

Abstract

Alzheimer's disease has been dominated by the amyloid cascade hypothesis, positing that amyloid-beta (Aβ) accumulation drives neurodegeneration[1]. However, the limited efficacy of anti-amyloid therapeutics indicates that downstream mechanisms—particularly synaptic degeneration and neuronal proteostasis collapse—warrant direct investigation. This report evaluates the research of Seth S. Margolis and colleagues, focusing on two molecular frameworks: (1) Ephexin5 (ARHGEF15), a RhoA-specific guanine nucleotide exchange factor reactivated by Aβ to drive dendritic spine loss; and (2) the Neuronal Membrane Proteasome (NMP), an ubiquitin-independent proteasome complex that links apolipoprotein E (ApoE) genetic variants to tau aggregation[5]. By examining in vitro, in vivo, and human post-mortem data, this analysis critically evaluates both frameworks. The work decouples some aspects of synaptic failure and tauopathy from obligate amyloid dependency, though significant unresolved questions remain regarding mechanism, translational feasibility, and therapeutic specificity[1].

Introduction

Alzheimer's disease represents the most prevalent neurodegenerative condition in aging populations, characterized clinically by progressive memory loss and histopathologically by amyloid-beta plaques and tau neurofibrillary tangles. The amyloid cascade hypothesis, formulated in the 1990s, posited that Aβ accumulation initiates a linear cascade leading to cognitive decline.

Yet clinical evidence challenges this model: the strongest biological correlate of cognitive decline is synapse loss, not overall amyloid load[12]. In 1991, Terry and colleagues demonstrated that neocortical synapse density showed correlation coefficients of 0.96[12] with cognitive impairment, whereas plaque density explained only a fraction of that variance[12]. This established the "synaptic slaughter" paradigm but did not displace the amyloid-centric framework from pharmaceutical development efforts.

Margolis's research program addresses this mechanistic gap by identifying specific molecular pathways active in development that become pathologically reactivated in aging. Two pillars merit evaluation:

1. **The Ephexin5 pathway**: Aβ-induced EphB2 loss triggers Ephexin5 accumulation, driving RhoA-mediated dendritic spine collapse through reactivation of developmental pruning mechanisms[1].
2. **The Neuronal Membrane Proteasome**: A non-canonical proteasome complex that modulates activity-induced protein synthesis and whose membrane localization is compromised by the ApoE4 genetic risk variant, creating conditions favorable to tau aggregation independent of Aβ pathology[5].

Literature Review: The Synaptic Paradigm



The Neuronal Membrane Proteasome (NMP) is a 20S complex at the plasma membrane that degrades newly synthesized proteins (like Tau) to maintain proteostasis. The ApoE4 risk variant selectively reduces NMP membrane localization. This failure of NMP-mediated degradation causes newly synthesized endogenous Tau to misfold and form sarkosyl-insoluble aggregates.

The field has oscillated between amyloid-centric and synapse-centric models. In 2000s, research identified soluble Aβ oligomers—rather than insoluble plaques—as the primary synaptotoxic agents[8]. Lennart Mucke's laboratory demonstrated that Aβ oligomers bind directly to the EphB2 receptor, triggering its proteasomal degradation and impairing NMDA receptor function and synaptic plasticity[22].

Margolis's 2010 Cell publication identified Ephexin5 as the molecular link downstream of EphB2 loss[3]. Under normal development, EphB2 phosphorylates Ephexin5, leading to its UBE3A-mediated degradation and permitting synaptogenesis[3]. Loss of EphB2 allows Ephexin5 accumulation, which then hyperactivates RhoA and drives spine collapse. This reframes AD pathology: synaptic degeneration is not a novel toxicity but inappropriate reactivation of a developmental pruning mechanism[1].

Methodology

Margolis's laboratory employs a systematic approach from biochemistry to in vivo behavior:

- **In vitro assays**: Cultured hippocampal neurons treated with soluble Aβ oligomers, analyzed via Western blotting, immunocytochemistry, GTPase pull-down assays, and live FRET imaging[16].
- **In vivo models**: hAPP transgenic mice (expressing human amyloid precursor protein); genetic crosses with Ephexin5-knockout mice; lentiviral shRNA knockdown in specific brain regions[1].
- **Behavioral testing**: Novel Place Preference test (spatial memory); Passive Avoidance test (associative learning)[1].

- **Human correlates**: Post-mortem hippocampal tissue stratified by Braak stage, validating that molecular alterations observed in mice occur in actual AD brains[1].

This multi-scale approach reduces the risk of isolated artifacts from any single model system.

Chapter 1: The Ephexin5-RhoA Axis

Developmental Physiology

Ephexin5 is a RhoA-specific guanine nucleotide exchange factor (GEF) that acts as a developmental "brake" on excitatory synapse formation. When a synapse is ready to mature, ephrin-B ligands bind EphB2, triggering phosphorylation of Ephexin5 at Tyrosine-361. This phosphorylation recruits UBE3A, an E3 ubiquitin ligase, which tags Ephexin5 for proteasomal degradation. Removal of Ephexin5 relieves RhoA-mediated actin depolymerization, allowing dendritic spine expansion[1]. In the healthy adult brain, Ephexin5 expression is minimal, restricted to high-plasticity regions[1].

Pathological Reactivation in Alzheimer's Disease

Margolis's 2017 Journal of Clinical Investigation study demonstrated this pathway's reactivation in AD:

1. **In vitro**: Soluble Aβ oligomers applied to mature hippocampal neurons caused rapid EphB2 loss and concurrent Ephexin5 elevation, measured by immunocytochemistry[1].
2. **In vivo**: Aβ oligomer injection into the dentate gyrus of wild-type mice reproduced Ephexin5 elevation. hAPP transgenic mice showed 2- to 3-fold Ephexin5 elevation in the DG and CA regions[1].
3. **Human tissue**: Post-mortem hippocampal samples from advanced Braak stage patients showed 2- to 3-fold Ephexin5 elevation versus age-matched controls, confirming this is not an artifact of transgenic overexpression[1].

Causal Evidence

Ephexin5 knockout in hAPP mice (Ephexin5^-/-) completely rescued mature dendritic spine density despite continued Aβ production and plaque formation[1]. Behavioral tests showed full restoration of spatial memory and associative learning[1]. Lentiviral shRNA-mediated knockdown of Ephexin5 in the dentate gyrus of presymptomatic hAPP mice prevented cognitive decline development[1].

These findings establish that Aβ requires Ephexin5 to execute synaptotoxic effects. Ephexin5 is minimally expressed in the healthy adult brain, making it a potentially selective drug target[1].

Chapter 2: Mechanistic Complexity—Ephexin5's Dual Role

A 2025 Science Advances study revealed that the initial linear model requires revision[31]. Ephexin5 is not exclusively a RhoA-specific GEF; it also activates Cdc42, and this substrate selectivity is dynamically regulated by neuronal activity and tyrosine phosphorylation[31].

Activity-Dependent Substrate Switching

During plasticity-inducing events (chemical long-term potentiation mimicking learning), Ephexin5 undergoes rapid dephosphorylation[31]. This shift in phosphorylation causes preferential activation of Cdc42 rather than RhoA[31]. Consequently, downstream of neuronal activity, Ephexin5 positively regulates synaptic growth and stabilization—the opposite of its resting state role[31].

Condition | Phosphorylation | Primary Target | Effect

Basal/resting | High | RhoA | Spine shrinkage
Active learning | Rapid dephosphorylation | Cdc42 | Spine growth
Alzheimer's disease | Hyperaccumulation | RhoA (overactivation) | Synaptic loss

The Angelman Syndrome Paradox Resolution

Angelman Syndrome, caused by UBE3A loss, would be expected to cause massive spine loss via Ephexin5 accumulation and RhoA hyperactivation[2]. Instead, spine density increases. The 2025 findings explain this: excess Ephexin5 in developing brains preferentially activates Cdc42-mediated stabilization rather than RhoA-mediated pruning[31].

Therapeutic Implications and Complications

The discovery of dual functionality substantially complicates drug development[31]. If Ephexin5-mediated Cdc42 activation is physiologically necessary for activity-dependent spine stabilization and memory formation, then global Ephexin5 inhibition could impair learning and memory consolidation in treated patients[31].

Simple small-molecule inhibitors (aggressively pursued after the 2017 study) lack the necessary pharmacological sophistication. Safe translation requires allosteric modulators or biased ligands that selectively prevent Ephexin5-RhoA interaction while preserving Ephexin5-Cdc42 activation during normal learning[7].

Chapter 3: The Neuronal Membrane Proteasome

Protein homeostasis disruption is a hallmark of neurodegenerative disease[16]. Historically, attention focused on the ubiquitin-proteasome system (26S proteasome) and autophagy[16]. Margolis's laboratory discovered an alternative: the Neuronal Membrane Proteasome (NMP)[16].

Architecture and Function

The NMP is an uncapped 20S proteasome core particle embedded in the neuronal plasma membrane (characterized 2017-2023)[45]. Unlike the canonical 26S proteasome (cytosolic/nuclear, ATP and ubiquitin-dependent), the NMP operates independently of ubiquitin and ATP[16].

Its primary function is to degrade the "nascentome"—proteins newly synthesized at the synapse immediately following neuronal activity[4]. When a neuron fires, local translation rapidly produces plasticity-related proteins (CaMKIIα, PSMD2) necessary for synapse strength modification. However, unchecked synthesis can cause hyperexcitability and destabilizing positive feedback loops[4].

The NMP degrades approximately one-third of nascent polypeptides directly at the membrane during active translation, providing rapid homeostatic modulation[4].

Evidence for NMP Function

In Xenopus laevis tadpole optic tectum (where transparency permits real-time calcium imaging), acute NMP inhibition (biotin-epoxomicin) induced neural circuit hypersynchronization and abolished learning-induced behavioral plasticity, demonstrating that NMP function is required for adaptive learning[4].

ApoE4, NMP Localization, and Tau Aggregation

Margolis's recent work (e.g., Paradise et al., 2022) connected NMP function to Apolipoprotein E (ApoE), whose E4 allele is the strongest genetic risk factor for late-onset AD[5].

Key finding: ApoE4 drastically reduces NMP localization to the neuronal plasma membrane compared to the neutral ApoE3 or protective ApoE2 isoforms[5]. This creates localized proteostatic failure at the synapse[5].

Critically, newly synthesized tau is exceptionally vulnerable to aggregation when NMP function is compromised[5]. NMP selective inhibition alone was sufficient to induce spontaneous aggregation of endogenous, newly synthesized tau into sarkosyl-insoluble, high-molecular-weight species—the hallmark of AD tauopathy[5].

The quantitative effect is substantial: ApoE4 lowers the tau aggregation threshold approximately 50-fold relative to ApoE3 (and 200-fold relative to ApoE2), entirely through NMP depletion[5]. This provides an ApoE4-mediated, Aβ-independent mechanism for tau pathology in genetic risk carriers[5].

Chapter 4: Genetic Architecture and Translational Challenges

ARHGEF15 in Human Genetics

Transcriptomic analysis of AD brains shows ARHGEF15 (Ephexin5) upregulation in both incipient and advanced disease[43]. Genome-wide epigenetic profiling reveals significant DNA methylation alterations at ARHGEF15 in AD, consistent with transcriptional dysregulation[44].

Notably, rare missense mutations in ARHGEF15 are identified as causal for autosomal dominant hereditary Cerebral Small Vessel Disease (CSVD)[45]. This indicates ARHGEF15 has distinct functions in cerebral endothelial cells, where it mediates VEGF-induced Cdc42 activation to promote angiogenesis and vascular growth[48].

The Pleiotropy Problem

ARHGEF15 is not brain-specific. The vascular involvement noted above creates a critical challenge: systemic Ephexin5 inhibitors designed to halt AD-related synaptic pruning risk compromising blood-brain barrier integrity or exacerbating cerebral small vessel disease through anti-angiogenic effects.

Safe translation requires targeted delivery: neuronal-specific proteolysis-targeting chimeras (PROTACs) that degrade Ephexin5 only in neurons, or highly specific allosteric modulators that avoid off-target effects in vascular tissue[7].

NMP Therapeutic Development

Because AD pathology in this model stems from loss of NMP membrane localization (driven by ApoE4), classical enzyme inhibitors are ineffective[5]. Therapeutic approaches must involve:

- Small molecules or gene therapies that rescue NMP trafficking to the plasma membrane
- Strategies enhancing 20S proteasome assembly at the membrane
- Synthetic compounds mimicking the yet-unidentified extracellular signaling peptides generated by normal NMP cleavage

Current pharmacology lacks established precedent for this class of intervention[4].

Critical Evaluation: Strengths and Limitations

Strengths

1. **Multi-scale validation**: Molecular findings tracked from biochemistry through in vivo behavior and human post-mortem tissue[1].

2. **Causal establishment**: Genetic deletion and lentiviral knockdown experiments, not merely correlational observations[1].

3. **Mechanism-specific**: Both frameworks identify specific molecular nodes rather than invoking "amyloid toxicity" generally[1].

4. **Genetic integration**: Findings align with transcriptomic and epigenetic AD data, and the ApoE4 connection addresses a major genetic risk factor directly[1].

5. **Honest recent updates**: The 2025 Science Advances findings on Ephexin5 dual functionality are incorporated, complicating the initial model rather than glossing over contradictions[31].

Significant Limitations and Uncertainties

1. **Ephexin5 as a complete explanation**: The model accounts for spine loss downstream of Aβ and ApoE4, but does not explain:

- Why Aβ accumulation initiates in the first place
- The contribution of neuroinflammation
- Non-synaptic neuronal dysfunction
- The timeline and sequence of tau emergence relative to Aβ

The framework is mechanistically sophisticated but still incomplete regarding AD initiation[1].

2. **NMP-tau causality remains partial**: NMP inhibition induces tau aggregation in vitro, and ApoE4 reduces membrane localization[1]. However:

- Whether this mechanism is *sufficient* to explain primary tauopathies (tau pathology without significant Aβ pathology) is unclear
- The identity and role of the signal peptides generated by NMP cleavage remain unknown
- Human evidence remains limited to post-mortem correlation and animal models

3. **Therapeutic complexity**: The discovery of Ephexin5's dual role (RhoA shrinkage vs. Cdc42 stabilization)[31] fundamentally complicates the drug development trajectory outlined in the original framework. Blunt inhibitors appear unviable; the field must develop novel biased ligands or allosteric modulators with no established precedent[7].

4. **Pleiotropy and off-target risk**: Both ARHGEF15's expression in vasculature and the NMP's broad distribution mean that systemic interventions carry genuine risk of unintended effects[451].

5. **Transgenic model limitations**: While hAPP transgenic mice show robust synaptic phenotypes, they may not fully recapitulate the temporal dynamics or cellular context of human AD[1]. The dependency on APP overexpression systems is a recurring concern[1].

6. **Reversibility unclear**: The experimental rescues (Ephexin5-/- mice) prevent pathology development; less is known about whether the same interventions can reverse established synaptic loss or cognitive deficits[1].

What This Analysis Cannot Determine

1. **Sufficiency of each mechanism**: While Margolis's frameworks account for certain aspects of AD pathology (spine loss, tau aggregation), they do not establish that targeting these pathways alone will robustly reverse cognitive decline in humans. Combination therapies may be necessary.

2. **Temporal and causal sequencing in human disease**: Which comes first—Aβ accumulation, NMP dysfunction, or tau emergence—remains unclear in human brain. Animal models cannot fully resolve this ambiguity.

3. **Cell-type specificity**: Both Ephexin5 and the NMP function in multiple cell types (neurons, glia, vasculature). Whether the pathology in AD is neuron-intrinsic or involves glial contribution is not definitively answered.

4. **Clinical translation timeline**: No human clinical trials have tested Ephexin5 inhibitors or NMP-targeting therapeutics. The feasibility of achieving the required pharmacological selectivity in patients remains speculative.

5. **Disease heterogeneity**: AD is likely heterogeneous. These mechanisms may dominate in some patients while being secondary in others. How to identify responders to Ephexin5 or NMP-based interventions is unaddressed.

6. **Long-term safety**: The off-target risks noted (vascular effects, learning impairment) are theoretical but untested. Chronic systemic pharmacological intervention carries unknown risks.

7. **Integration with other pathways**: Neuroinflammation, metabolic dysfunction, and mitochondrial pathology are documented in AD but not mechanistically integrated into the Ephexin5-NMP framework.

Conclusion

Margolis's research program provides specific molecular frameworks addressing a genuine gap in AD mechanism: how does Aβ-driven EphB2 loss translate into structural synaptic collapse, and how does genetic risk (ApoE4) predispose to tau without obligate Aβ dependency?

The Ephexin5 pathway offers a plausible mechanistic link between EphB2 depletion and dendritic spine loss through RhoA hyperactivation, reframing AD synaptic failure as inappropriate reactivation of developmental pruning. The NMP framework provides an Aβ-independent mechanism connecting ApoE4 genetic risk to tau aggregation through impaired membrane-localized protein homeostasis.

Both frameworks are grounded in careful experimental work spanning biochemistry, in vivo imaging, behavior, and human tissue correlation. However, the 2025 discovery of Ephexin5's dual functionality substantially complicates therapeutic development, the NMP-tau mechanism remains incomplete (with critical signaling peptides unidentified), and neither framework fully explains AD initiation or accounts for other documented pathological processes.

The work represents a significant advance in understanding downstream mechanisms of synaptic failure and specific aspects of genetic risk. Translation to safe, effective human therapeutics will require solutions to pleiotropy, development of unprecedented pharmacology (biased Ephexin5 ligands, NMP trafficking modulators), and resolution of unanswered questions regarding causality and mechanism. This is a strong but partial framework, not a complete solution to AD pathogenesis.

Works Cited

1. Seth Margolis Paper.pdf

2. Researchers Identify Novel Potential New Pathway and Target for Alzheimer's Disease, accessed March 23, 2026, https://neurologytoday.aan.com/doi/10.1097/01.NT.0000521708.80399.66

3. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2967209/
4. Neuronal membrane proteasomes regulate neuronal circuit activity in vivo and are required for learning-induced behavioral plasticity | PNAS, accessed March 23, 2026, https://www.pnas.org/doi/10.1073/pnas.2216537120
5. ApoE isoforms differentially regulate neuronal membrane proteasomes to shift the threshold for pathological aggregation of endogenous Tau | bioRxiv, accessed March 23, 2026, https://www.biorxiv.org/content/10.1101/2022.11.29.518293v1.full-text
6. (PDF) Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/390249669_Activity-dependent_regulatio n_of_Cdc42_by_Ephexin5_drives_synapse_growth_and_stabilization
7. The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease - PMC - NIH, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6715421/
8. Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5950662/
9. The Future Of Alzheimer's Disease: Some Hope, But Daunting Numbers, accessed March 23, 2026, https://margolisbloom.com/planning-for-life/the-future-of-alzheimers-disease-some -hope-but-daunting-numbers/
10. Reassessing the Amyloid Cascade Hypothesis of Alzheimer's Disease - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2680505/
11. Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?| JNEUROLOGY, accessed March 23, 2026, https://www.jneurology.com/articles/primary-agerelated-tauopathy-and-the-amyloid -cascade-hypothesis-the-exception-that-proves-the-rule-neuromed-1-1059.php
12. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment - PubMed, accessed March 23, 2026, https://pubmed.ncbi.nlm.nih.gov/1789684/
13. Correcting Synapse Loss in the Alzheimer's Disease Brain - BrightFocus, accessed March 23, 2026, https://www.brightfocus.org/grant/correcting-synapse-loss-in-the-alzheimers-disea se-brain/
14. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice - JCI, accessed March 23, 2026, https://www.jci.org/articles/view/85504
15. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5409082/
16. Mechanisms of ubiquitin-independent proteasomal degradation and their roles in
age-related neurodegenerative disease - PubMed, accessed March 23, 2026, https://pubmed.ncbi.nlm.nih.gov/39990094/
17. Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-Photon in vivo Imaging of Transgenic Mouse Models - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.20 20.592607/full
18. Remembering Robert D. Terry at a Time of Change in the World of Alzheimer's Disease, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6750985/
19. Synaptic Basis of Alzheimer's Disease: Focus on Synaptic Amyloid Beta, P-Tau and Mitochondria - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7770124/
20. Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/synaptic-neuroscience/articles/10.3389/fnsyn.2 023.1129036/full
21. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques | PNAS, accessed March 23, 2026, https://www.pnas.org/doi/10.1073/pnas.0811698106
22. Perspectives on Treatment of Alzheimer's Disease: A Closer Look into EphB2 Depletion, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6596747/
23. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3030448/
24. EphB2: potential therapeutic target for Alzheimer's disease, accessed March 23, 2026, https://journals.biologists.com/dmm/article/4/1/2/53405/EphB2-potential-therapeuti c-target-for-Alzheimer-s
25. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6604917/
26. Eph receptors at synapses - Ip Lab - Molecular Neuroscience Laboratory, accessed March 23, 2026, https://iplab.hkust.edu.hk/pdf/Reviews%20pdf/2012_03%20CellSig.pdf
27. Seth Margolis - The Solomon H Snyder Department of Neuroscience, accessed March 23, 2026, https://neuroscience.jhu.edu/research/faculty/109
28. QnAs with Hollis T. Cline - PNAS, accessed March 23, 2026, https://www.pnas.org/doi/10.1073/pnas.2221189120
29. PKCε Inhibits Neuronal Dendritic Spine Development through Dual Phosphorylation of Ephexin5 - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6371982/
30. RhoA Signaling in Neurodegenerative Diseases - MDPI, accessed March 23,
2026, https://www.mdpi.com/2073-4409/11/9/1520

31. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11939064/
32. EphBs: an integral link between synaptic function and synaptopathies - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3631563/
33. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/315663352_Reducing_expression_of_sy napse-restricting_protein_Ephexin5_ameliorates_Alzheimer's-like_impairment_in_ mice
34. Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice - PubMed, accessed March 23, 2026, https://pubmed.ncbi.nlm.nih.gov/28346227/
35. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse, accessed March 23, 2026, https://discovery.researcher.life/article/activity-dependent-regulation-of-cdc42-by-e phexin5-drives-synapse-growth-and-stabilization/b5a88ea6d3343e63be35e28748 582237
36. Rac-maninoff and Rho-vel: The symphony of Rho-GTPase signaling ..., accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9707551/
37. Full article: Rac-maninoff and Rho-vel: The symphony of Rho-GTPase signaling at excitatory synapses - Taylor & Francis, accessed March 23, 2026, https://www.tandfonline.com/doi/full/10.1080/21541248.2021.1885264
38. In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11408168/
39. A?? Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome | Request PDF - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/253126561_A_Immunotherapy_Leads_t o_Clearance_of_Early_but_Not_Late_Hyperphosphorylated_Tau_Aggregates_via _the_Proteasome
40. Neuronal membrane proteasomes homeostatically regulate neural circuit activity in vivo and are required for learning-induced behavioral plasticity | bioRxiv, accessed March 23, 2026, https://www.biorxiv.org/content/10.1101/2022.01.29.478314.full
41. Neuronal membrane proteasomes regulate neuronal circuit activity in vivo and are required for learning-induced behavioral plasticity - PubMed, accessed March 23, 2026, https://pubmed.ncbi.nlm.nih.gov/36630455/
42. The proteasome: A key modulator of nervous system function, brain aging, and neurodegenerative disease - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10133520/
43. Human Gene Set: BLALOCK_ALZHEIMERS_DISEASE_UP, accessed March 23, 2026,
https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/BLALOCK_ALZHEIME RS_DISEASE_UP.html
44. Distinct sex-specific DNA methylation differences in Alzheimer's disease - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9479371/
45. Mutations in ARHGEF15 cause autosomal dominant hereditary cerebral small vessel disease and osteoporotic fracture | Request PDF - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/369300186_Mutations_in_ARHGEF15_c ause_autosomal_dominant_hereditary_cerebral_small_vessel_disease_and_oste oporotic_fracture
46. Potential Biological and Genetic Links Between Dementia and Osteoporosis: A Scoping Review - PMC, accessed March 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12333915/
47. Understanding Everyday Needs of Older Adults with Cognitive Impairments: Insights from Subject Matter Experts | Request PDF - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/346390343_Understanding_Everyday_N eeds_of_Older_Adults_with_Cognitive_Impairments_Insights_from_Subject_Matt er_Experts
48. Emerging Roles of Ephexins in Physiology and Disease - MDPI, accessed March 23, 2026, https://www.mdpi.com/2073-4409/8/2/87
49. Changes in Gene Expression Profiling and Phenotype in Aged Multidrug Resistance Protein 4-Deficient Mouse Retinas - MDPI, accessed March 23, 2026, https://www.mdpi.com/2076-3921/10/3/455
50. ARHGEF15 Gene - Ma'ayan Lab – Computational Systems Biology, accessed March 23, 2026, https://maayanlab.cloud/Harmonizome/gene/ARHGEF15
51. Neuronal membrane proteasome-derived peptides modulate NMDAR-dependent neuronal signaling to promote changes in gene expression - PubMed, accessed March 23, 2026, https://pubmed.ncbi.nlm.nih.gov/37910253/